MedPage Today 
(8/27, Fiore) reports, "Waiting to treat cytomegalovirus (CMV) in
kidney transplant patients may deliver better long-term outcomes than
blanket preventive drugs," according to a
study
published online in the Journal of the American Society of Nephrology.
Investigators found, "in a small randomized trial," that "organ graft
survival was significantly worse for those having CMV prophylaxis
(P=0.044) compared
with those who received therapy for CMV viremia, and more of these
patients had interstitial fibrosis and tubular atrophy though the
difference wasn't significant (38% versus 19%, P=0.22)."
No comments:
Post a Comment